KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Debt: 2012-2024

Historic Total Debt for Halozyme Therapeutics (HALO) over the last 11 years, with Dec 2024 value amounting to $1.5 billion.

  • Halozyme Therapeutics' Total Debt rose 0.44% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 0.44%. This contributed to the annual value of $1.5 billion for FY2024, which is 0.44% up from last year.
  • As of FY2024, Halozyme Therapeutics' Total Debt stood at $1.5 billion, which was up 0.44% from $1.5 billion recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Total Debt peaked at $1.5 billion during FY2022, and registered a low of $397.2 million during FY2020.
  • Over the past 3 years, Halozyme Therapeutics' median Total Debt value was $1.5 billion (recorded in 2024), while the average stood at $1.5 billion.
  • As far as peak fluctuations go, Halozyme Therapeutics' Total Debt surged by 1,932.69% in 2020, and later dropped by 0.45% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Total Debt (Yearly) stood at $397.2 million in 2020, then soared by 120.70% to $876.7 million in 2021, then spiked by 71.80% to $1.5 billion in 2022, then decreased by 0.45% to $1.5 billion in 2023, then climbed by 0.44% to $1.5 billion in 2024.